Increased neuroplasticity and hippocampal microglia activation in a mice model of rapid antidepressant treatment

Behavioural Brain Research

Volumn 311, Issue , 2016, Pages 392-402

  Muzio, Luca ^a   Brambilla, Valentina ^a   Calcaterra, Lorenza ^a   D'Adamo, Patrizia ^a   Martino, Gianvito ^a   Benedetti, Francesco ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Depression; Exercise; Sleep deprivation; Wnt7

Indexed keywords

ANTIDEPRESSANT AGENT; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; WNT7A PROTEIN; TRANSCRIPTOME; WNT PROTEIN; WNT7A PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL HUSBANDRY; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC SPINE; DENTATE GYRUS; DENTATE HILUS; DEPRESSION; FORCED SWIM TEST; HIPPOCAMPUS; IMMUNOFLUORESCENCE; INNATE IMMUNITY; LONG TERM POTENTIATION; MALE; MICROARRAY ANALYSIS; MICROGLIA; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLEEP DEPRIVATION; SYNAPTOGENESIS; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; KINESIOTHERAPY; MACROPHAGE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; RUNNING;

ANIMALS; CELL PROLIFERATION; DENDRITIC SPINES; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; EXERCISE THERAPY; HIPPOCAMPUS; MACROPHAGES; MALE; MICE, INBRED C57BL; MICROGLIA; NEURONAL PLASTICITY; RUNNING; SLEEP DEPRIVATION; TRANSCRIPTOME; WNT PROTEINS;

EID: 84974533858     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2016.05.063     Document Type: Article

References (78)

1. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet 2013.
2. Hendrie C., Pickles A., Stanford S.C., Robinson E. The failure of the antidepressant drug discovery process is systemic. J. Psychopharmacol. (Oxf.) 2013, 27:407-413. (discussion 13-6).
3. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 2006, 110:135-370.
4. Benedetti F., Smeraldi E. Neuroimaging and genetics of antidepressant response to sleep deprivation: implications for drug development. Curr. Pharm. Des. 2009, 15:2637-2649.
5. Tardito D., Perez J., Tiraboschi E., Musazzi L., Racagni G., Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol. Rev. 2006, 58:115-134.
6. Zarate C.A., Mathews D.C., Furey M.L. Human biomarkers of rapid antidepressant effects. Biol. Psychiatry 2013, 73:1142-1155.
7. Benedetti F., Terman M. Much ado about. . .a moody clock. Biol. Psychiatry 2013, 74:236-237.
8. Benedetti F., Colombo C. Sleep deprivation in mood disorders. Neuropsychobiology 2011, 64:141-151.
9. Gardner J.P., Fornal C.A., Jacobs B.L. Effects of sleep deprivation on serotonergic neuronal activity in the dorsal raphe nucleus of the freely moving cat. Neuropsychopharmacology 1997, 17:72-81.
10. Benedetti F., Fresi F., Maccioni P., Smeraldi E. Behavioural sensitization to repeated sleep deprivation in a mice model of mania. Behav. Brain Res. 2008, 187:221-227.
11. Benedetti F., Barbini B., Fulgosi M.C., Colombo C., Dallaspezia S., Pontiggia A., et al. Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. J. Clin. Psychiatry 2005, 66:1535-1540.
12. Benedetti F., Riccaboni R., Locatelli C., Poletti S., Dallaspezia S., Colombo C. Rapid treatment response of suicidal symptoms to lithium, sleep deprivation, and light therapy (chronotherapeutics) in drug-resistant bipolar depression. J. Clin. Psychiatry 2014, 75:133-140.
13. Martiny K., Refsgaard E., Lund V., Lunde M., Sorensen L., Thougaard B., et al. A 9-week randomized trial comparing a chronotherapeutic intervention (wake and light therapy) to exercise in major depressive disorder patients treated with duloxetine. J. Clin. Psychiatry 2012, 73:1234-1242.
14. Mura G., Moro M.F., Patten S.B., Carta M.G. Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. CNS Spectr. 2014, 1-13.
15. Hoffman B.M., Babyak M.A., Craighead W.E., Sherwood A., Doraiswamy P.M., Coons M.J., et al. Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. Psychosom. Med. 2011, 73:127-133.
16. Trivedi M.H., Greer T.L., Grannemann B.D., Chambliss H.O., Jordan A.N. Exercise as an augmentation strategy for treatment of major depression. J. Psychiatr. Pract. 2006, 12:205-213.
17. Aguiar A.S., Stragier E., da Luz Scheffer D., Remor A.P., Oliveira P.A., Prediger R.D., et al. Effects of exercise on mitochondrial function, neuroplasticity and anxio-depressive behavior of mice. Neuroscience 2014, 271:56-63.
18. Lu J., Xu Y., Hu W., Gao Y., Ni X., Sheng H., et al. Exercise ameliorates depression-like behavior and increases hippocampal BDNF level in ovariectomized rats. Neurosci. Lett. 2014, 573:13-18.
19. Krogh J., Rostrup E., Thomsen C., Elfving B., Videbech P., Nordentoft M. The effect of exercise on hippocampal volume and neurotrophines in patients with major depression-a randomized clinical trial. J. Affect. Disord. 2014, 165:24-30.
20. Benedetti F., Dallaspezia S., Fulgosi M.C., Barbini B., Colombo C., Smeraldi E. Phase advance is an actimetric correlate of antidepressant response to sleep deprivation and light therapy in bipolar depression. Chronobiol. Int. 2007, 24:921-937.
21. Royant-Parola S., Borbely A.A., Tobler I., Benoit O., Widlocher D. Monitoring of long-term motor activity in depressed patients. Br. J. Psychiatry 1986, 149:288-293.
22. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338:68-72.
23. Machado-Vieira R., Soeiro-De-Souza M.G., Richards E.M., Teixeira A.L., Zarate C.A. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J. Biol. Psychiatry 2013, 15(2):84-95.
24. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
25. Hussaini S.M., Choi C.I., Cho C.H., Kim H.J., Jun H., Jang M.H. Wnt signaling in neuropsychiatric disorders: ties with adult hippocampal neurogenesis and behavior. Neurosci. Biobehav. Rev. 2014, 47:369-383.
26. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
27. Liu Y., Ho R.C., Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J. Affect. Disord. 2012, 139:230-239.
28. Padmos R.C., Van Baal G.C., Vonk R., Wijkhuijs A.J., Kahn R.S., Nolen W.A., et al. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study. Arch. Gen. Psychiatry 2009, 66:957-965.
29. Drexhage R.C., Knijff E.M., Padmos R.C., Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev. Neurother. 2010, 10:59-76.
30. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 2008, 42:151-157.
31. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
32. Beumer W., Gibney S.M., Drexhage R.C., Pont-Lezica L., Doorduin J., Klein H.C., et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J. Leukoc. Biol. 2012, 92:959-975.
33. Huang C.T., Chiang R.P., Chen C.L., Tsai Y.J. Sleep deprivation aggravates median nerve injury-induced neuropathic pain and enhances microglial activation by suppressing melatonin secretion. Sleep 2014, 37:1513-1523.
34. Wisor J.P., Schmidt M.A., Clegern W.C. Evidence for neuroinflammatory and microglial changes in the cerebral response to sleep loss. Sleep 2011, 34:261-272.
35. Benedetti F. Antidepressant chronotherapeutics for bipolar depression. Dialogues Clin. Neurosci. 2012, 14:401-411.
36. Hill T., Lewicki P. General linear models. Statistics: Methods and Applications. A Comprehensive Reference for Science, Industry, and Data Mining 2006, 245-276. StatSoft, Tulsa (OK), (Chapter 18).
37. Cirelli C., Tononi G. Differential expression of plasticity-related genes in waking and sleep and their regulation by the noradrenergic system. J. Neurosci. 2000, 20:9187-9194.
38. Thompson C.L., Wisor J.P., Lee C.K., Pathak S.D., Gerashchenko D., Smith K.A., et al. Molecular and anatomical signatures of sleep deprivation in the mouse brain. Front. Neurosci. 2010, 4:165.
39. Paolicelli R.C., Bisht K., Tremblay M.E. Fractalkine regulation of microglial physiology and consequences on the brain and behavior. Front. Cell. Neurosci. 2014, 8:129.
40. Guyon A. CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front. Cell. Neurosci. 2014, 8:65.
41. Fernando C.V., Kele J., Bye C.R., Niclis J.C., Alsanie W., Blakely B.D., et al. Diverse roles for Wnt7a in ventral midbrain neurogenesis and dopaminergic axon morphogenesis. Stem Cells Dev. 2014, 23:1991-2003.
42. Qu Q., Sun G., Murai K., Ye P., Li W., Asuelime G., et al. Wnt7a regulates multiple steps of neurogenesis. Mol. Cell. Biol. 2013, 33:2551-2559.
43. Ciani L., Boyle K.A., Dickins E., Sahores M., Anane D., Lopes D.M., et al. Wnt7a signaling promotes dendritic spine growth and synaptic strength through Ca(2)(+)/Calmodulin-dependent protein kinase II. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:10732-10737.
44. Sahores M., Gibb A., Salinas P.C. Frizzled-5, a receptor for the synaptic organizer Wnt7a, regulates activity-mediated synaptogenesis. Development 2010, 137:2215-2225.
45. Gogolla N., Galimberti I., Deguchi Y., Caroni P. Wnt signaling mediates experience-related regulation of synapse numbers and mossy fiber connectivities in the adult hippocampus. Neuron 2009, 62:510-525.
46. Wirz-Justice A., Benedetti F., Terman M. Chronotherapeutics for affective disorders. A Clinician's Manual for Light and Wake Therapy 2013, Karger, Basel. II ed.
47. Guzowski J.F., McNaughton B.L., Barnes C.A., Worley P.F. Environment-specific expression of the immediate-early gene arc in hippocampal neuronal ensembles. Nat. Neurosci. 1999, 2:1120-1124.
48. McIntyre C.K., Miyashita T., Setlow B., Marjon K.D., Steward O., Guzowski J.F., et al. Memory-influencing intra-basolateral amygdala drug infusions modulate expression of arc protein in the hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10718-10723.
49. Pevzner A., Miyashita T., Schiffman A.J., Guzowski J.F. Temporal dynamics of arc gene induction in hippocampus: relationship to context memory formation. Neurobiol. Learn Mem. 2012, 97:313-320.
50. Miyashita T., Kubik S., Haghighi N., Steward O., Guzowski J.F. Rapid activation of plasticity-associated gene transcription in hippocampal neurons provides a mechanism for encoding of one-trial experience. J. Neurosci. 2009, 29:898-906.
51. Bramham C.R., Worley P.F., Moore M.J., Guzowski J.F. The immediate early gene arc/arg3.1: regulation, mechanisms, and function. J. Neurosci. 2008, 28:11760-11767.
52. Shepherd J.D., Rumbaugh G., Wu J., Chowdhury S., Plath N., Kuhl D., et al. Arc/Arg3.1 mediates homeostatic synaptic scaling of AMPA receptors. Neuron 2006, 52:475-484.
53. Dubiela F.P., Queiroz C.M., Moreira K.D., Nobrega J.N., Sita L.V., Tufik S., et al. AMPA receptors mediate passive avoidance deficits induced by sleep deprivation. Behav. Brain Res. 2013, 257:189-196.
54. Canali P., Sferrazza Papa G., Casali A.G., Fecchio M., Pigorini A., Schiena G., et al. Changes of cortical excitability as biomarkers of antidepressant response in bipolar depression. Bipolar Disord. 2014, 16:809-819.
55. Casarotto S., Canali P., Rosanova M., Pigorini A., Fecchio M., Mariotti M., et al. Assessing the effects of electroconvulsive therapy on cortical excitability by means of transcranial magnetic stimulation and electroencephalography. Brain Topogr. 2012, 26(2):326-337.
56. Cornwell B.R., Salvadore G., Furey M., Marquardt C.A., Brutsche N.E., Grillon C., et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol. Psychiatry 2012, 72:555-561.
57. Vyazovskiy V.V., Cirelli C., Pfister-Genskow M., Faraguna U., Tononi G. Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep. Nat. Neurosci. 2008, 11:200-208.
58. Benedetti F., Calabrese G., Bernasconi A., Cadioli M., Colombo C., Dallaspezia S., et al. Spectroscopic correlates of antidepressant response to sleep deprivation and light therapy: a 3: 0 tesla study of bipolar depression. Psychiatry Res. 2009, 173:238-242.
59. Park H.J., Kang W.S., Paik J.W., Kim J.W. Effect of valproic acid through regulation of NMDA receptor-ERK signaling in sleep deprivation rats. J. Mol. Neurosci. 2012, 47:554-558.
60. Novati A., Hulshof H.J., Granic I., Meerlo P. Chronic partial sleep deprivation reduces brain sensitivity to glutamate N-methyl-D-aspartate receptor-mediated neurotoxicity. J. Sleep Res. 2012, 21:3-9.
61. de Bartolomeis A., Sarappa C., Buonaguro E.F., Marmo F., Eramo A., Tomasetti C., et al. Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2013, 46:1-12.
62. Dyrvig M., Hansen H.H., Christiansen S.H., Woldbye D.P., Mikkelsen J.D., Lichota J. Epigenetic regulation of arc and c-fos in the hippocampus after acute electroconvulsive stimulation in the rat. Brain Res. Bull. 2012, 88:507-513.
63. Cotman C.W., Berchtold N.C., Christie L.A. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007, 30:464-472.
64. Peebles C.L., Yoo J., Thwin M.T., Palop J.J., Noebels J.L., Finkbeiner S. Arc regulates spine morphology and maintains network stability in vivo. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18173-18178.
65. Hall A.C., Brennan A., Goold R.G., Cleverley K., Lucas F.R., Gordon-Weeks P.R., et al. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol. Cell. Neurosci. 2002, 20:257-270.
66. Hanson N.D., Owens M.J. Nemeroff CB. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology 2011, 36:2589-2602.
67. Tanti A., Belzung C. Hippocampal neurogenesis: a biomarker for depression or antidepressant effects? Methodological considerations and perspectives for future research. Cell Tissue Res. 2013, 354:203-219.
68. Malykhin N.V. Coupland NJ: hippocampal neuroplasticity in major depressive disorder. Neuroscience 2015.
69. Jedynak P., Kos T., Sandi C., Kaczmarek L., Filipkowski R.K. Mice with ablated adult brain neurogenesis are not impaired in antidepressant response to chronic fluoxetine. J. Psychiatr. Res. 2014, 56:106-111.
70. Sugama S., Fujita M., Hashimoto M., Conti B. Stress induced morphological microglial activation in the rodent brain: involvement of interleukin-18. Neuroscience 2007, 146:1388-1399.
71. Kubera M., Obuchowicz E., Goehler L., Brzeszcz J., Maes M. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2011, 35:744-759.
72. Kim S., Hwang Y., Webster M.J., Lee D. Differential activation of immune/inflammatory response-related co-expression modules in the hippocampus across the major psychiatric disorders. Mol. Psychiatry 2015, 21(3):376-385.
73. Reus G.Z., Fries G.R., Stertz L., Badawy M., Passos I.C., Barichello T., et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 2015, 300:141-154.
74. Gillin J.C., Buchsbaum M., Wu J., Clark C., Bunney W. Sleep deprivation as a model experimental antidepressant treatment: findings from functional brain imaging. Depress. Anxiety 2001, 14:37-49.
75. Ren M., Cao V., Ye Y., Manji H.K., Wang K.H. Arc regulates experience-dependent persistent firing patterns in frontal cortex. J. Neurosci. 2014, 34:6583-6595.
76. Li Y., Pehrson A.L., Waller J.A., Dale E., Sanchez C., Gulinello M. A critical evaluation of the activity-regulated cytoskeleton-associated protein (Arc/Arg3.1)'s putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression. Front. Neurosci. 2015, 9:279.
77. Vai B., Poletti S., Radaelli D., Dallaspezia S., Bulgarelli C., Locatelli C., et al. Successful antidepressant chronotherapeutics enhance fronto-limbic neural responses and connectivity in bipolar depression. Psychiatry Res. 2015, 233:243-253.
78. Benedetti F., Bernasconi A., Blasi V., Cadioli M., Colombo C., Falini A., et al. Neural and genetic correlates of antidepressant response to sleep deprivation - A functional magnetic resonance imaging study of moral valence decision, in bipolar depression. Arch. Gen. Psychiatry 2007, 64:179-187.